Company intelligence / Profile preview

Valeo Pharma

Kirkland, Quebec, Canadacda-amc.ca ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

As of early February 2025, Valeo Pharma has a portfolio of approximately twelve commercialized products across respiratory/allergy, ophthalmology, neurology, oncology, and specialty hospital products. The company has demonstrated significant revenue growth over the past three years with a focus on licensing/acquiring Canadian rights to innovative drugs. In February 2025 it was acquired by Xediton Pharmaceuticals Inc., which will continue operating the business under its existing structure.[1–6]

Therapeutic areas: PulmonologyCardiovascularOphthalmologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Small moleculeBiologicDeviceFlavonoid formulation
Industry: Biotech

Drug pipeline

1 asset

synacthen depot

Commercial

Partnerships

Novartis/SandozVeru

Beyond the preview

Go deeper on Valeo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valeo Pharma.

Explore the full profile